PMID- 29768323
OWN - NLM
STAT- MEDLINE
DCOM- 20180525
LR  - 20240326
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 20
DP  - 2018 May
TI  - Efficacy and risks of anticoagulation for cerebral venous thrombosis.
PG  - e10506
LID - 10.1097/MD.0000000000010506 [doi]
LID - e10506
AB  - BACKGROUND AND PURPOSE: Cerebral venous thrombosis (CVT) is a rare but 
      life-threatening disease. Timely and proper treatments are the keys in saving 
      patients' life and preventing from permanent neurological deficits. We performed 
      this network meta-analysis to evaluate the role of anticoagulation in CVT, 
      especially for the patients accompanied with hemorrhagic stroke. METHODS: PubMed, 
      Embase, Web of Science, Cochrane Database, and Chinese Biomedical (CBM) databases 
      were searched comprehensively to select eligible articles (up to 30 June 2017). 
      Network meta-analysis was performed based on classical frequency statistics. 
      RESULTS: Around 14 studies comprising 1135 cases were included. Overall analysis 
      showed that low-molecular weight heparin (LMWH) and unfractionated heparin (UFH) 
      were more effective (LMWH vs placebo: OR 4.76, 95%CI: 2.56-8.33; UFH vs placebo: 
      OR 4.12, 95%CI: 2.17-8.33), and safe (LMWH vs placebo: OR 0.22, 95%CI: 
      0.069-0.65; UFH vs placebo: OR 0.28, 95%CI: 0.058-0.99) than placebo in the 
      management of CVT. Besides, LMWH showed more advantages than UFH; As for the 
      patients accompanied with hemorrhagic stroke, LMWH and UFH were also better than 
      placebo (efficacy: LMWH vs placebo: OR 20, 95%CI: 5.56-100; UFH vs placebo: OR 
      12.5, 95%CI: 3.7-33.3; safety: LMWH vs placebo: OR 0.18, 95%CI: 0.04-0.77; UFH vs 
      placebo: OR 0.16, 95%CI: 0.04-0.6) in the management of CVT. In addition, LMWH 
      was more effective than UFH for the patients accompanied with hemorrhagic stroke. 
      CONCLUSION: Anticoagulant treatment with heparin is safe and beneficial for 
      patients with CVT, even for those accompanied with hemorrhagic stroke. Besides, 
      LMWH is better than UFH in the management of CVT.
FAU - Xu, Weilin
AU  - Xu W
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine Brain 
      Research Institute Collaborative Innovation Center for Brain Science, Zhejiang 
      University, Hangzhou, Zhejiang, China.
FAU - Gao, Liansheng
AU  - Gao L
FAU - Li, Tao
AU  - Li T
FAU - Shao, Anwen
AU  - Shao A
FAU - Zhang, Jianmin
AU  - Zhang J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Heparin/adverse effects/*therapeutic use
MH  - Humans
MH  - Intracranial Hemorrhages/*drug therapy
MH  - Intracranial Thrombosis/*drug therapy
PMC - PMC5976280
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2018/05/17 06:00
MHDA- 2018/05/26 06:00
PMCR- 2018/05/18
CRDT- 2018/05/17 06:00
PHST- 2018/05/17 06:00 [entrez]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2018/05/26 06:00 [medline]
PHST- 2018/05/18 00:00 [pmc-release]
AID - 00005792-201805180-00003 [pii]
AID - MD-D-17-07928 [pii]
AID - 10.1097/MD.0000000000010506 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(20):e10506. doi: 10.1097/MD.0000000000010506.